Clinical Trial

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Name: CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study — clinical trial record (NCT06136364)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Record status

This record was last updated November 18, 2023 (before its estimated August 15, 2024 completion). Its status may not reflect the trial's current state.

Summary

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.

Trial Details

NCT Number	NCT06136364
Lead Sponsor	Hebei Senlang Biotechnology Inc., Ltd.
Conditions	T-lymphoblastic Lymphoma, T-ALL
Enrollment	9 participants
Start Date	2023-08-15
Primary Completion	2024-08-15 (estimated)
Study Completion	2038-08-14 (estimated)
Updated on ClinicalTrials.gov	2023-11-18